Go Pro
NASDAQ:JBIO

Jade Biosciences Q3 2025 Earnings Report

Jade Biosciences logo
$21.79 +0.45 (+2.13%)
As of 03:45 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Jade Biosciences EPS Results

Actual EPS
-$0.48
Consensus EPS
-$0.57
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Jade Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Jade Biosciences Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
Friday, November 14, 2025
Conference Call Time
7:00AM ET

Jade Biosciences Earnings Headlines

Jade Biosciences: Duration Is The Real Product
HC Wainwright Expects Stronger Earnings for Jade Biosciences
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing total outflows to 14 billion. At the same time, the World Gold Council recorded the highest quarterly central bank gold buying on record, with buyers taking physical delivery instead of paper shares.tc pixel
Jade Biosciences (NASDAQ:JBIO) Price Target Raised to $77.00
Jade Biosciences Inc JBIO
See More Jade Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Jade Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jade Biosciences and other key companies, straight to your email.

About Jade Biosciences

Jade Biosciences (NASDAQ:JBIO) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation. Preclinical studies have demonstrated promising activity in models of atopic dermatitis, psoriasis‐associated itch and other dermatologic conditions, supporting the progression of these candidates into human trials. Jade Biosciences’ pipeline strategy includes both topical and systemic formulations to broaden the therapeutic scope across multiple indications.

Founded in the mid‐2010s and incorporated in Delaware, Jade Biosciences maintains its headquarters in New Haven, Connecticut. The company’s management team draws on experience from established pharmaceutical and biotechnology organizations, combining expertise in medicinal chemistry, dermatology and clinical development. Listed on the Nasdaq under the ticker JBIO, Jade Biosciences is working to advance its pipeline through clinical milestones while preparing for potential partnerships and regulatory filings in the United States and other key markets.

View Jade Biosciences Profile